|
GB725228A
(en)
|
1952-06-19 |
1955-03-02 |
Roche Products Ltd |
Substituted carbamic acid esters and process for the manufacture thereof
|
|
BE640616A
(cg-RX-API-DMAC7.html)
|
1962-12-19 |
|
|
|
|
NL130759C
(cg-RX-API-DMAC7.html)
|
1965-10-07 |
|
|
|
|
US3492397A
(en)
|
1967-04-07 |
1970-01-27 |
Warner Lambert Pharmaceutical |
Sustained release dosage in the pellet form and process thereof
|
|
US4060598A
(en)
|
1967-06-28 |
1977-11-29 |
Boehringer Mannheim G.M.B.H. |
Tablets coated with aqueous resin dispersions
|
|
US3538214A
(en)
|
1969-04-22 |
1970-11-03 |
Merck & Co Inc |
Controlled release medicinal tablets
|
|
US4173626A
(en)
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
|
US4593034A
(en)
|
1984-04-06 |
1986-06-03 |
A. H. Robins Company, Inc. |
2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
|
|
IE63474B1
(en)
|
1987-12-24 |
1995-04-19 |
Wyeth John & Brother Ltd |
Heterocyclic compounds
|
|
ATE85217T1
(de)
|
1988-08-04 |
1993-02-15 |
Synthelabo |
Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
|
|
US5549892A
(en)
|
1988-12-23 |
1996-08-27 |
Genzyme Corporation |
Enhanced in vivo uptake of glucocerebrosidase
|
|
US5236838A
(en)
|
1988-12-23 |
1993-08-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
|
IT1228293B
(it)
|
1989-02-06 |
1991-06-07 |
Angeli Inst Spa |
Benzoderivati di composti eterociclici contenenti azoto.
|
|
DK443489D0
(da)
|
1989-09-08 |
1989-09-08 |
Ferrosan As |
Substituerede urinstofforbindelser, deres fremstilling og anvendelse
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
GB9106571D0
(en)
|
1991-03-27 |
1991-05-15 |
Erba Carlo Spa |
Derivatives of substituted imidazol-2-one and process for their preparation
|
|
US5968502A
(en)
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
|
AU685225B2
(en)
|
1994-02-10 |
1998-01-15 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel carbamate derivative and medicinal composition containing the same
|
|
JPH08198751A
(ja)
|
1995-01-19 |
1996-08-06 |
Yamanouchi Pharmaceut Co Ltd |
カルバメート誘導体
|
|
JP2000500139A
(ja)
|
1995-11-08 |
2000-01-11 |
アメリカン・ホーム・プロダクツ・コーポレイション |
1−アザビシクロヘプタン誘導体およびそれらの医薬用途
|
|
SE9600683D0
(sv)
|
1996-02-23 |
1996-02-23 |
Astra Ab |
Azabicyclic esters of carbamic acids useful in therapy
|
|
EE9900034A
(et)
|
1996-07-29 |
1999-08-16 |
Pharmacia & Upjohn Ab |
Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
|
|
EP1027069B1
(en)
|
1997-10-29 |
2006-07-26 |
Genzyme Corporation |
Gene therapy for gaucher disease
|
|
CN1332726A
(zh)
|
1998-11-02 |
2002-01-23 |
卫福有限公司 |
吡咯烷化合物及其药物用途
|
|
US6953855B2
(en)
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
|
FR2791678B1
(fr)
|
1999-03-30 |
2001-05-04 |
Synthelabo |
Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
|
|
PL357099A1
(en)
|
2000-02-07 |
2004-07-12 |
Abbott Gmbh & Co.Kg |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
|
AU2001266100B9
(en)
|
2000-06-27 |
2005-10-06 |
Laboratorios S.A.L.V.A.T., S.A. |
Carbamates derived from arylalkylamines
|
|
US6492386B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
WO2002015662A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
|
EP1345937B1
(en)
|
2000-12-22 |
2005-09-28 |
Almirall Prodesfarma AG |
Quinuclidine carbamate derivatives and their use as m3 antagonists
|
|
DE60216830T2
(de)
|
2001-02-06 |
2007-06-14 |
Pfizer Products Inc., Groton |
Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
|
|
JP2003267977A
(ja)
|
2002-03-14 |
2003-09-25 |
Yamanouchi Pharmaceut Co Ltd |
キヌクリジン誘導体
|
|
DE10211415A1
(de)
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
|
ES2203327B1
(es)
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2393331T3
(es)
|
2002-07-17 |
2012-12-20 |
Actelion Pharmaceuticals Ltd. |
Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
|
|
AU2003248122A1
(en)
|
2002-07-25 |
2004-02-16 |
Kotobuki Pharmaceutical Co., Ltd. |
Sodium channel inhibitor
|
|
SE0202430D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
New Compounds
|
|
ATE378048T1
(de)
|
2002-12-06 |
2007-11-15 |
The Feinstein Inst Medical Res |
Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
|
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
|
TW200529860A
(en)
|
2003-12-22 |
2005-09-16 |
Astrazeneca Ab |
Nicotinic acetylcholine receptor ligands
|
|
GB0400812D0
(en)
|
2004-01-14 |
2004-02-18 |
Celltech R&D Ltd |
Novel compounds
|
|
JP2007186422A
(ja)
|
2004-01-28 |
2007-07-26 |
Astellas Pharma Inc |
アリールスルフィド誘導体
|
|
JP2008504282A
(ja)
|
2004-06-23 |
2008-02-14 |
ザ ファインスタイン インスティテュート フォー メディカル リサーチ |
コリンレセプターの薬理活性により腸閉塞を処置する方法
|
|
BRPI0517701A8
(pt)
|
2004-11-10 |
2018-01-23 |
Genzyme Corp |
métodos de tratamento de diabetes mellitus
|
|
EP1891048A1
(en)
|
2005-06-11 |
2008-02-27 |
Vernalis (R&D) Limited |
Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
|
|
CN101312968A
(zh)
|
2005-09-23 |
2008-11-26 |
记忆药物公司 |
吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
|
|
SG131819A1
(en)
|
2005-11-07 |
2007-05-28 |
Chikka Pte Ltd |
Buddy-based cross-carrier messaging system
|
|
JP2009523845A
(ja)
|
2006-01-23 |
2009-06-25 |
クリスタルゲノミクス インコーポレーテッド |
たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
|
|
US20090318491A1
(en)
|
2006-01-27 |
2009-12-24 |
Yale Univeristy |
Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
|
|
WO2008096870A1
(ja)
|
2007-02-09 |
2008-08-14 |
Astellas Pharma Inc. |
アザ架橋環化合物
|
|
EP2142197A4
(en)
|
2007-03-30 |
2010-11-10 |
Amicus Therapeutics Inc |
METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
|
|
CA2707360A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Diphenyl substituted alkanes
|
|
EP2211856A4
(en)
|
2007-11-29 |
2011-02-09 |
Hospital For Sick Children |
COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
|
|
JP2011529500A
(ja)
|
2008-07-28 |
2011-12-08 |
ジェンザイム コーポレーション |
虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
WO2010091104A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Glucosylceramide synthase inhibitors
|
|
WO2010091164A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Inhibitors of glucosylceramide synthase
|
|
CN102438988B
(zh)
|
2009-04-21 |
2015-06-24 |
内尔维阿诺医学科学有限公司 |
作为hsp90抑制剂的间苯二酚衍生物
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EP2456438A2
(en)
|
2009-07-23 |
2012-05-30 |
Novartis AG |
Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
|
|
CA2773133A1
(en)
|
2009-08-28 |
2011-03-03 |
Edward H. Schuchman |
Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
|
|
US20110183938A1
(en)
|
2009-12-16 |
2011-07-28 |
Genentech, Inc. |
1,7-diazacarbazoles and methods of use
|
|
AU2011327113B9
(en)
|
2010-11-12 |
2015-07-30 |
Shionogi & Co., Ltd. |
Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
|
|
LT2685986T
(lt)
|
2011-03-18 |
2020-03-10 |
Genzyme Corporation |
Gliukozilceramido sintazės slopiklis
|
|
US20140228575A1
(en)
|
2011-06-22 |
2014-08-14 |
Isochem |
Process for the Preparation of Solifenacin and Salts Thereof
|
|
AU2012272815B2
(en)
|
2011-06-22 |
2017-09-07 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
PL4066849T3
(pl)
|
2012-09-11 |
2025-06-16 |
Hospira Australia Pty Ltd |
Preparaty daptomycyny i ich zastosowania
|
|
JO3713B1
(ar)
|
2013-03-15 |
2021-01-31 |
Genzyme Corp |
أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
|
|
TW201900625A
(zh)
|
2013-03-15 |
2019-01-01 |
美商健臻公司 |
製備葡糖基神經醯胺合成酶抑制劑之方法
|
|
EP3079695B1
(en)
|
2013-12-11 |
2021-03-17 |
Genzyme Corporation |
Glucosylceramide synthase inhibitors
|
|
TW201642855A
(zh)
*
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
EP3412296B1
(en)
*
|
2016-02-05 |
2025-11-12 |
Kyungpook National University Industry-Academic Cooperation Foundation |
Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
|
|
JP7585561B2
(ja)
*
|
2019-02-04 |
2024-11-19 |
プリレニア ニューロセラピューティクス リミテッド |
パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
|
|
PT3920912T
(pt)
|
2019-02-04 |
2025-09-09 |
Genzyme Corp |
Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
|
|
SG11202107844UA
(en)
|
2019-02-04 |
2021-08-30 |
Genzyme Corp |
Methods for treating symptoms and disorders associated with lysosomal storage diseases
|
|
IL295255A
(en)
|
2020-02-03 |
2022-10-01 |
Genzyme Corp |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|